Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.50 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.50 |
| ▸ | HSPA8 | P11142 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5982945 | 1.00 | SLC29A1 (0.50) | SLC29A1HSPA5HSPA8RXFP1HIF1A | |
| SCHEMBL5983106 | 0.87 | HSPA5 (0.52) | SLC29A1HSPA5HSPA8RXFP1HIF1A | |
| SCHEMBL5982786 | 0.87 | HSPA8 (0.52) | SLC29A1HSPA5HSPA8RXFP1HIF1A | |
| SCHEMBL5983118 | 0.87 | HSPA5 (0.52) | SLC29A1HSPA5HSPA8RXFP1HIF1A | |
| SCHEMBL5982633 | 0.86 | HSPA8 (0.51) | SLC29A1HSPA5HSPA8RXFP1HIF1A | |
| SCHEMBL5982083 | 0.86 | RXFP1 (0.51) | SLC29A1HSPA5HSPA8RXFP1HIF1A | |
| SCHEMBL5982074 | 0.86 | RXFP1 (0.51) | SLC29A1HSPA5HSPA8RXFP1HIF1A | |
| SCHEMBL5982628 | 0.86 | HSPA8 (0.51) | SLC29A1HSPA5HSPA8RXFP1HIF1A | |
| SCHEMBL6267133 | 0.86 | HIF1A (0.49) | RXFP1HIF1AADORA3ADORA2ATP53 | |
| SCHEMBL6267131 | 0.86 | HIF1A (0.49) | RXFP1HIF1AADORA3ADORA2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1634888-A2 | Synthesis of 2'-deoxy-L-nucleosides | Pharmasset Limited (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1600451-A2 | Synthesis of 2'-deoxy-l-nucleosides | Pharmasset Limited (US) | 2005-11-30 | — | — | EP | disclosed |
| EP-1600452-A2 | Synthesis of 2'-deoxy-L-nucleosides | Pharmasset Limited (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20050090660-A1 | 2'-deoxy-L-nucleosides | PHARMASSET, INC. | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090660-A1 | 2'-deoxy-L-nucleosides | CCNH, ADAR, NSUN2 | SLC29A1 380/4885HSPA5 4472/4885HSPA8 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.